Literature DB >> 28404485

State-level gonorrhea rates and expedited partner therapy laws: insights from time series analyses.

K Owusu-Edusei1, R Cramer2, H W Chesson2, T L Gift2, J S Leichliter2.   

Abstract

OBJECTIVE: In this study, we examined state-level monthly gonorrhea morbidity and assessed the potential impact of existing expedited partner therapy (EPT) laws in relation to the time that the laws were enacted. STUDY
DESIGN: Longitudinal study.
METHODS: We obtained state-level monthly gonorrhea morbidity (number of cases/100,000 for males, females and total) from the national surveillance data. We used visual examination (of morbidity trends) and an autoregressive time series model in a panel format with intervention (interrupted time series) analysis to assess the impact of state EPT laws based on the months in which the laws were enacted.
RESULTS: For over 84% of the states with EPT laws, the monthly morbidity trends did not show any noticeable decreases on or after the laws were enacted. Although we found statistically significant decreases in gonorrhea morbidity within four of the states with EPT laws (Alaska, Illinois, Minnesota, and Vermont), there were no significant decreases when the decreases in the four states were compared contemporaneously with the decreases in states that do not have the laws.
CONCLUSION: We found no impact (decrease in gonorrhea morbidity) attributable exclusively to the EPT law(s). However, these results do not imply that the EPT laws themselves were not effective (or failed to reduce gonorrhea morbidity), because the effectiveness of the EPT law is dependent on necessary intermediate events/outcomes, including sexually transmitted infection service providers' awareness and practice, as well as acceptance by patients and their partners. Published by Elsevier Ltd.

Entities:  

Keywords:  Expedited partner therapy; Gonorrhea; Law; Time series analysis

Mesh:

Year:  2017        PMID: 28404485      PMCID: PMC6800101          DOI: 10.1016/j.puhe.2017.02.012

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  15 in total

1.  Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.

Authors:  Matthew R Golden; William L H Whittington; H Hunter Handsfield; James P Hughes; Walter E Stamm; Matthew Hogben; Agnes Clark; Cheryl Malinski; Jennifer R L Helmers; Katherine K Thomas; King K Holmes
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

2.  Patient-delivered partner treatment for male urethritis: a randomized, controlled trial.

Authors:  Patricia Kissinger; Hamish Mohammed; Gwangi Richardson-Alston; Jami S Leichliter; Stephanie N Taylor; David H Martin; Thomas A Farley
Journal:  Clin Infect Dis       Date:  2005-07-19       Impact factor: 9.079

3.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

4.  The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea.

Authors:  Thomas L Gift; Patricia Kissinger; Hamish Mohammed; Jami S Leichliter; Matthew Hogben; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2011-11       Impact factor: 2.830

5.  Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV.

Authors:  Matthew R Golden; Matthew Hogben; H Hunter Handsfield; Janet S St Lawrence; John J Potterat; King K Holmes
Journal:  Sex Transm Dis       Date:  2003-06       Impact factor: 2.830

Review 6.  Partner Services in Sexually Transmitted Disease Prevention Programs: A Review.

Authors:  Matthew Hogben; Dayne Collins; Brooke Hoots; Kevin OʼConnor
Journal:  Sex Transm Dis       Date:  2016-02       Impact factor: 2.830

7.  The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

Authors:  Kwame Owusu-Edusei; Harrell W Chesson; Thomas L Gift; Guoyu Tao; Reena Mahajan; Marie Cheryl Bañez Ocfemia; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

Review 8.  Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008.

Authors:  Catherine Lindsey Satterwhite; Elizabeth Torrone; Elissa Meites; Eileen F Dunne; Reena Mahajan; M Cheryl Bañez Ocfemia; John Su; Fujie Xu; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

9.  Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial.

Authors:  Julia A Schillinger; Patricia Kissinger; Helene Calvet; William L H Whittington; Ray L Ransom; Maya R Sternberg; Stuart M Berman; Charlotte K Kent; David H Martin; M Kim Oh; H Hunter Handsfield; Gail Bolan; Lauri E Markowitz; J Dennis Fortenberry
Journal:  Sex Transm Dis       Date:  2003-01       Impact factor: 2.830

10.  Evaluation of a population-based program of expedited partner therapy for gonorrhea and chlamydial infection.

Authors:  Matthew R Golden; James P Hughes; Devon D Brewer; King K Holmes; William L H Whittington; Matthew Hogben; Cheryl Malinski; Anne Golding; H Hunter Handsfield
Journal:  Sex Transm Dis       Date:  2007-08       Impact factor: 2.830

View more
  1 in total

1.  Dyadic Intervention for Sexually Transmitted Infection Prevention in Urban Adolescents and Young Adults (The SEXPERIENCE Study): Protocol for a Randomized Controlled Trial.

Authors:  Maria Trent; Hasiya Eihuri Yusuf; Julia Rowell; Jacquelin Toppins; Colin Woods; Steven Huettner; Camille Robinson; Errol L Fields; Arik V Marcell; Ralph DiClemente; Pamela Matson
Journal:  JMIR Res Protoc       Date:  2022-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.